DNMT3A and leukemia: The data we obtained from the in vitro and in vivo experiments support the hypothesis that oridonin effectively inhibits DNMT3A R882 mutation-driven clonal hematopoiesis and leukemia, and this provides the preclinical evidence for the possible clinical investigation of oridonin for DNMT3A-mutant leukemia.